113 related articles for article (PubMed ID: 9246969)
1. Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels.
Hayashi M; Numaguchi M; Watabe H; Enomoto H; Yaoi Y
Acta Obstet Gynecol Scand; 1997 Jul; 76(6):590-5. PubMed ID: 9246969
[TBL] [Abstract][Full Text] [Related]
2. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of fosfomycin on cisplatin-induced nephrotoxicity in patients with lung cancer.
Rojanasthien N; Kumsorn B; Atikachai B; Leotrakul S; Thongprasert S
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):121-5. PubMed ID: 11396752
[TBL] [Abstract][Full Text] [Related]
4. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
6. The effect of fosfomycin on nedaplatin-induced nephrotoxicity in rats.
Yoshiyama Y; Yamaguchi K; Matsuo K; Kurokawa M; Kanke M
J Infect Chemother; 2005 Feb; 11(1):14-7. PubMed ID: 15729482
[TBL] [Abstract][Full Text] [Related]
7. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
8. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
9. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of cisplatin-induced ototoxicity by fosfomycin.
Schweitzer VG; Dolan DF; Abrams GE; Davidson T; Snyder R
Laryngoscope; 1986 Sep; 96(9 Pt 1):948-58. PubMed ID: 3747696
[TBL] [Abstract][Full Text] [Related]
11. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of fleroxacin against the nephrotoxicity of isepamicin in rats.
Yazaki T; Yoshiyama Y; Wong P; Beauchamp D; Kanke M
Biol Pharm Bull; 2002 Apr; 25(4):516-9. PubMed ID: 11995935
[TBL] [Abstract][Full Text] [Related]
13. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of cisplatin effect on tubular function in children on chemotherapy.
Zareifar S; Jafari H; Geramizadeh B; Basiratnia M; Golafshan H; Cohan N; Mehravar Z; Hamidi R
Pediatr Hematol Oncol; 2013 Feb; 30(1):18-24. PubMed ID: 23163346
[TBL] [Abstract][Full Text] [Related]
15. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
16. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
Saad SY; Al-Rikabi AC
Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
[TBL] [Abstract][Full Text] [Related]
18. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.
Nakamura T; Kokuryo T; Hashimoto Y; Inui KI
J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats.
Hayashi T; Watanabe Y; Kumano K; Kitayama R; Muratani T; Yasuda T; Saikawa I; Katahira J; Kumada T; Shimizu K
Antimicrob Agents Chemother; 1989 Apr; 33(4):513-8. PubMed ID: 2729945
[TBL] [Abstract][Full Text] [Related]
20. Possible mechanism of PNS protection against cisplatin-induced nephrotoxicity in rat models.
Liu X; Huang Z; Zou X; Yang Y; Qiu Y; Wen Y
Toxicol Mech Methods; 2015; 25(5):347-54. PubMed ID: 25598344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
